AI English summary of an SEC filing — figures as filed
Cencora CORThe company said quarterly revenue rose $7.3 billion (10.9%) from the prior year, and nine-month revenue rose $21.7 billion (11.2%) from the prior year period, mainly driven by growth in the U.S. Healthcare Solutions segment.
Key points
AI summaryThe company said quarterly revenue rose $7.3 billion (10.9%) from the prior year, and nine-month revenue rose $21.7 billion (11.2%) from the prior year period, mainly driven by growth in the U.S. Healthcare Solutions segment.
Cencora attributed the revenue growth in U.S. Healthcare Solutions to higher sales of GLP-1-class products, which rose $2.1 billion in the quarter and $5.5 billion over 9 months. It said the segment's gross profit margin was 2.30% for the quarter, down 6 basis points from the prior year.
The company said operating activities generated $2,484.3 million in cash over the 9 months ended June 30, 2024, and financing activities in the same period included share repurchases of $986.4 million and dividend payments of $315.2 million.
The company said its estimated remaining liability for settled opioid-related lawsuits, including those under the Distributor Settlement Agreement, was about $5.1 billion on its consolidated balance sheet as of June 30, 2024, and that it expects the amount to be paid over the next 14 years.
Key figures
Quarter ended June 30, 2024
- Revenue
- $74.2B
- Operating income
- $672M
- Net income
- $483M
- EPS
- $2.42
- Gross profit
- $2.4B
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
Revenue Growth Led by U.S. Healthcare Solutions
The company said quarterly revenue rose $7.3 billion (10.9%) from the prior year, and nine-month revenue rose $21.7 billion (11.2%) from the prior year period, mainly driven by growth in the U.S. Healthcare Solutions segment.
Source · Based on the MD&A text of the filing
GLP-GLP-1 Sales Growth and Gross Margin
Cencora attributed the revenue growth in U.S. Healthcare Solutions to higher sales of GLP-1-class products, which rose $2.1 billion in the quarter and $5.5 billion over 9 months. It said the segment's gross profit margin was 2.30% for the quarter, down 6 basis points from the prior year.
Source · Based on the MD&A text of the filing
9-Month Operating Cash Flow and Share Repurchases
The company said operating activities generated $2,484.3 million in cash over the 9 months ended June 30, 2024, and financing activities in the same period included share repurchases of $986.4 million and dividend payments of $315.2 million.
Source · Based on the MD&A text of the filing
Remaining Estimated Opioid Litigation Liability
The company said its estimated remaining liability for settled opioid-related lawsuits, including those under the Distributor Settlement Agreement, was about $5.1 billion on its consolidated balance sheet as of June 30, 2024, and that it expects the amount to be paid over the next 14 years.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…